Skip to main content

Table 1 Baseline comparison of children randomized to daily and three times a week dosing schedule.

From: Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules

Baseline characteristics Daily
(n= 128)
Three times a week (n= 148) Total
(n= 276)
P*Value
Sex (%)     
   Male 57.0 55.4 56.3 0.81
Age (months)     0.45
   Median 29.7 21.8 25.9  
   (IQR) (13.1 to 47.7) (10.2 to 52.6) (11.9 to 51.0)  
Age (years; %)     0.50
   < 1 year 23.4 26.4 25.0  
   1-4 years 51.6 44.6 47.8  
   > 4 years 25.0 29.0 27.1  
Study drug (%)     0.39
   Placebo 35.2 40.5 38.0  
   Isoniazid 64.8 59.5 62.1  
Site (%)     0.55
   RCCH 52.3 48.0 50.0  
   TCH 47.7 52.0 50.0  
CDC clinical stage (%)     0.95
   N or A 14.8 13.5 14.1  
   B 65.6 66.9 66.3  
   C 19.5 19.6 19.6  
CDC immune stage (%)     0.09
   1 22.7 34.5 29.0  
   2 46.1 37.2 41.3  
   3 31.2 28.4 29.7  
On HAART at randomization (%) 10.9 9.5 10.1 0.7
Started HAART during study (%) 64.8 58.8 61.6 0.32
No tap water in house (%) 50.0 53.7 52.2 0.63
No electricity in house (%) 16.5 23.7 20.3 0.18
No flush toilet in house (%) 55.1 56.8 56.0 0.81
Not a brick house (%) 41.7 45.6 43.8 0.54
Number of people living in house     0.5
   Med 5 5 5  
   (IQR) (3 to 6) (4 to 6.5) (3 to 6)  
Number of people in house (%)     0.31
   ≤ 5 67.7 61.5 64.4  
   > 5 32.3 38.5 35.6  
  1. Figures are medians (interquartile range) for continuous variables and percentage of children for categorical variables.
  2. * P-values from Fisher's exact test for categorical data or two-sample Wilcoxon rank-sum (Mann-Whitney) test for continuous data
  3. RCCH = Red Cross War Memorial Children's Hospital; TCH = Tygerberg Children's Hospital; CDC = Centers for Disease Control and Prevention; HAART = highly active antiretroviral therapy.